M&A and equity raisings

6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

US deals dated after 30 September 2026 are still being collected.

Deal size
Custom range

124 deals · US$156bndisclosed · Biotech · Clear

Columns
M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value US$m Sector Advisers
Oct 2026 mAbxience –FreseniusAcquisitionCompleted1,946.9Biotech+1 Lazard (buy-side)
Sep 2026 Marea Therapeutics –Lisata TherapeuticsAcquisitionAnnounced–Biotech+1 Goodwin (sell-side)
Sep 2026 Aethlon Medical ––MergerAnnounced–Biotech Gibson DunnMaxim GroupProcopio, Cory, Hargreaves & SavitchWedbush Securities
Sep 2026 Santersus AG –Xenetic BiosciencesAcquisitionAnnounced–Medtech+1 Mintz (sell-side)Lex Futura (sell-side)Holland & Knight (buy-side)Canaccord Genuity (buy-side)
Sep 2026 RIGImmune –Leyden LabsAcquisitionCompleted–Biotech+1 Gunderson Dettmer (sell-side)
Sep 2026 Organica UK ––MergerAnnounced–Chemicals+2 Brown Rudnick
Sep 2026 Polaris Demea AgroMotion Equity PartnersAcquisitionAnnounced–Food Ingredients+2 Goodwin (sell-side)
Sep 2026 trispecific T cell-engager (TCE) asset Chimagen BiosciencesGSKAsset saleAnnounced750.0Biotech+2 Cooley (sell-side)Latham & Watkins (buy-side)
Sep 2026 Cellipont Bioservices ––MergerCompleted–Pharma Services+2 William Blair
Sep 2026 Orbis Medicines –Novo NordiskStakeAnnounced–Biotech+1 Latham & Watkins (buy-side)
Aug 2026 Merida Biosciences –Eli Lilly and CompanyAcquisitionAnnounced2,875.0Biotech+1 Goodwin (sell-side)Centerview Partners (sell-side)Ropes & Gray (buy-side)
Aug 2026 Ambros Therapeutics –Werewolf TherapeuticsMergerAnnounced500.0Biotech+2 Sidley Austin (buy-side)Cooley (sell-side)Piper Sandler (buy-side)
Aug 2026 Alesta Therapeutics –BioMarin PharmaceuticalAcquisitionAnnounced275.0Biotech+2 J.P. Morgan (sell-side)Goodwin (sell-side)NautaDutilh (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side)
Aug 2026 Slate Medicines –Fulcrum TherapeuticsMergerAnnounced–Biotech+1 Goodwin (buy-side)Cooley (sell-side)Wedbush Securities (sell-side)Leerink Partners (buy-side)
Aug 2026 Redx Pharma –Skye BioscienceAcquisitionAnnounced–Biotech+1 Wedbush Securities (sell-side)Cooley (sell-side)Stifel (buy-side)Morrison & Foerster (buy-side)
Aug 2026 Actio Biosciences –Jazz PharmaceuticalsAcquisitionAnnounced820.0Biotech+2 J.P. Morgan (sell-side)Centerview Partners (sell-side)Cooley (sell-side)Moelis & Company (buy-side)Hogan Lovells Cadwalader (buy-side)
Aug 2026 assets, business operations and customer relationships –NueCell BioAsset saleAnnounced–Pharma Services+1 Goodwin (buy-side)
Aug 2026 Cy Biopharma –Ensysce BiosciencesAcquisitionCompleted–Biotech+1 H.C. Wainwright & Co.Orrick (sell-side)Wedbush Securities (sell-side)Troutman Pepper Locke (buy-side)Tungsten Advisors (buy-side)
Aug 2026 Alkeus Pharmaceuticals –Tarsus PharmaceuticalsAcquisitionAnnounced450.0Biotech+2 Jefferies (sell-side)Latham & Watkins (sell-side)Barclays (buy-side)Gunderson Dettmer (buy-side)
Aug 2026 MIMETAS –BRUKERAcquisitionCompleted–Life Sciences+1 Raymond James
Jul 2026 Neurimmune's royalty interest in AstraZeneca's cliramitug NeurimmuneRoyalty PharmaAsset saleAnnounced250.0Pharma+1 Goodwin (buy-side)
Jul 2026 Synlogic ––MergerAnnounced–Biotech+1 Lucid Capital Markets (sell-side)Mintz (sell-side)Fenwick & West (buy-side)
Jul 2026 Vidya Therapeutics –Processa PharmaceuticalsAcquisitionCompleted–Biotech+1 Leerink Partners (sell-side)Cooley (sell-side)Tungsten Advisors (buy-side)Katten Muchin Rosenman (buy-side)
Jul 2026 Forte Biosciences –argenx SEAcquisitionAnnounced2,200.0Biotech+1 Guggenheim Securities (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)Goldman Sachs (buy-side)Freshfields (buy-side)Innisfree M&A (buy-side)
Jul 2026 OHB Pediatrics Ltd. d/b/a Oak Hill Bio –Research Alliance Corporation IIIMergerAnnounced–Biotech+2 Goodwin (sell-side)Leerink Partners (buy-side)Cooley (buy-side)
Jul 2026 Neuphoria Therapeutics –Scancell HoldingsAcquisitionAnnounced–Biotech+1 H.C. Wainwright & Co. (sell-side)WG Partners (sell-side)Winston Taylor (sell-side)Leerink Partners (buy-side)Cooley (buy-side)
Jul 2026 BioLife Solutions –RepligenAcquisitionAnnounced1,500.0Life Sciences+1 Centerview Partners (sell-side)K&L Gates (sell-side)Goodwin (buy-side)Perella Weinberg Partners (buy-side)Goldman Sachs (buy-side)
Jul 2026 Avere Therapeutics –Hansoh Pharmaceutical Group Co.StakeAnnounced–Biotech+2 Goodwin (buy-side)
Jul 2026 AtaiBeckley –Eli Lilly and CompanyAcquisitionAnnounced2,800.0Biotech+2 Moelis & Company (sell-side)Centerview Partners (sell-side)Latham & Watkins (sell-side)Citi (sell-side)Cooley (sell-side)Sullivan & Cromwell (sell-side)Goldman Sachs (buy-side)Ropes & Gray (buy-side)
Jul 2026 Kira Pharmaceuticals –Jasper TherapeuticsAcquisitionCompleted–Biotech+1 Piper Sandler (sell-side)DLA Piper (sell-side)H.C. Wainwright & Co. (buy-side)Paul Hastings (buy-side)
Jul 2026 Senti Holdings, Inc. (Midco) Senti Biosciences HoldingsCeladon Partners SPV 35AcquisitionAnnounced–Biotech+2 Lincoln International (sell-side)Gunderson Dettmer (sell-side)McDermott Will & Schulte (buy-side)
Jul 2026 Avere Therapeutics –NextCureMergerAnnounced–Biotech+1 Sullivan & CromwellSidley Austin (buy-side)Gibson Dunn (sell-side)Wedbush Securities (sell-side)Tungsten Advisors (buy-side)
Jul 2026 iRenix Medical –Tarsus PharmaceuticalsAcquisitionAnnounced75.0Ophthalmology+2 Piper Sandler (sell-side)DLA Piper (sell-side)Gunderson Dettmer (buy-side)
Jul 2026 Memo Therapeutics –IpsenAcquisitionAnnounced231.1Biotech Goodwin (sell-side)Centerview Partners (sell-side)
Jul 2026 Myricx Bio –NovartisAcquisitionAnnounced1,100.0Biotech+1 Goodwin (sell-side)
Jul 2026 Crinetics Pharmaceuticals –Vertex PharmaceuticalsAcquisitionAnnounced10,000.0Biotech+2 Lazard (buy-side)J.P. Morgan (sell-side)Leerink Partners (sell-side)Paul, Weiss (sell-side)Morrison & Foerster (sell-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side)
Jul 2026 BridgeBio –Sixth StreetStakeCompleted1,000.0Biotech+1 Sullivan & Cromwell (buy-side)Evercore (buy-side)
Jul 2026 Kestrel –AbbVieAcquisitionAnnounced–Biotech Lazard
Jul 2026 MTX652 Mission TherapeuticsDimerixAsset saleAnnounced292.0Biotech+1 Guggenheim Securities (sell-side)
Jul 2026 MeiraGTx Holdings –Oberland Capital ManagementStakeAnnounced–Biotech+1 Latham & Watkins (sell-side)
Jun 2026 Kartos Therapeutics –IpsenAcquisitionAnnounced450.0Biotech+1 Goldman Sachs (sell-side)PJT Partners (sell-side)DLA Piper (sell-side)Orrick (buy-side)
Jun 2026 Talawar Therapeutics –JATT II Acquisition CorpMergerAnnounced–Biotech+1 Cooley (sell-side)Greenberg Traurig (buy-side)
Jun 2026 Theravance Biopharma –ZymeworksAcquisitionPending929.0Pharma+1 Lazard (sell-side)Evercore (sell-side)Skadden, Arps, Slate, Meagher & Flom (sell-side)Arthur Cox (sell-side)Kirkland & Ellis (buy-side)Matheson (buy-side)MTS Health Partners (buy-side)
Jun 2026 Remix Therapeutics –Passage BioMergerPending–Biotech+2 Wedbush SecuritiesRBC Capital MarketsCanaccord GenuityLatham & Watkins (sell-side)Fenwick & West (buy-side)
Jun 2026 Serapha Bio –Boundless BioMergerPending–Biotech+1 Wedbush Securities (sell-side)Gibson Dunn (sell-side)Goodwin (sell-side)Lucid Capital Markets (buy-side)Latham & Watkins (buy-side)
Jun 2026 Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program Sangamo TherapeuticsEli Lilly and CompanyAsset saleCompleted–Biotech+1 Raymond JamesPaul, Weiss (buy-side)
Jun 2026 Apogee Therapeutics –AbbVieAcquisitionPending10,900.0Biotech+2 Goldman Sachs (sell-side)Jefferies (sell-side)Kirkland & Ellis (sell-side)Paul, Weiss (buy-side)Morgan Stanley (buy-side)
Jun 2026 4E Therapeutics –Eli Lilly and CompanyAcquisitionCompleted–Biotech+1 Wilson Sonsini Goodrich & Rosati (sell-side)
Jun 2026 Azora Therapeutics –Adial PharmaceuticalsAsset saleCompleted–Biotech+2 Lucid Capital Markets (sell-side)Honigman (sell-side)Oppenheimer & Co. (buy-side)Blank Rome (buy-side)
Jun 2026 Nuvalent –GSKAcquisitionPending10,600.0Biotech+2 Sullivan & CromwellCenterview Partners (sell-side)Ropes & Gray (sell-side)Jefferies (sell-side)Sidley Austin (sell-side)Leerink Partners (buy-side)Citi (buy-side)Davis Polk (buy-side)Slaughter and May (buy-side)Innisfree M&A (buy-side)

Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.